Primary Immune Deficiency (PID) - Pipeline Review, H2 2019

Primary Immune Deficiency (PID) - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H2 2019, provides an overview of the Primary Immune Deficiency (PID) (Genetic Disorders) pipeline landscape.

Primary immunodeficiency is defined as weaken immune system, allowing repeated infections and other health problems to occur more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, digestive problems, such as cramping, loss of appetite, nausea and diarrhea.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II and Preclinical stages are 1, 9, 3 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 10, 1 and 3 molecules, respectively.

Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Primary Immune Deficiency (PID) - Overview
Primary Immune Deficiency (PID) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Primary Immune Deficiency (PID) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development
ADMA Biologics Inc
AlloVir Inc
Biotest AG
Cellective BioTherapy Inc
Clinigen Group Plc
Enzyvant Sciences Ltd
Evolve Biologics Inc
GC Pharma
GigaGen Inc
Grifols SA
Liminal BioSciences Inc
Mustang Bio Inc
Octapharma AG
Orchard Therapeutics Plc
Rocket Pharmaceuticals Inc
Sangamo Therapeutics Inc
Taiga Biotechnologies Inc
Takeda Pharmaceutical Co Ltd
X4 Pharmaceuticals Inc
Primary Immune Deficiency (PID) - Drug Profiles
aldesleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALVR-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody for Primary Immune Deficiency Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic 1 for Genetic Disorders and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Genetic Disorders and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-595 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Severe Combined Immune Deficiency and Graft Versus Host Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for RAG-Deficient Severe Combined Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for X-Linked SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Adenosine Deaminase for Adenosine Deaminase Deficiency Related SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Artemis for Severe Combined Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Artemis for Severe Combined Immunodeficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate IL-2 Gamma Receptor for SCID-X1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate IL-2 Gamma Receptor for X-Linked SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate IL2RG for SCID-X1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate IL2RG for X-Linked SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hyaluronidase (recombinant, human) + immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mavorixafor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MB-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPL-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RVT-802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
simoladagene autotemcel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CXCL12 for WHIM Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Strimvelis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBX-1400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
X-4P003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Primary Immune Deficiency (PID) - Dormant Projects
Primary Immune Deficiency (PID) - Discontinued Products
Primary Immune Deficiency (PID) - Product Development Milestones
Featured News & Press Releases
Nov 12, 2019: X4 Pharmaceuticals receives Breakthrough Therapy Designation from the FDA for Mavorixafor for the treatment of WHIM syndrome
Oct 15, 2019: Rocket Pharmaceuticals announces upcoming presentation on RPL-201 at the European Society of Gene and Cell Therapy Annual Congress
Sep 06, 2019: Rocket Pharmaceuticals begins gene therapy in LAD-I study
Aug 12, 2019: Kedrion Biopharma announces first patient enrolled in CARES10, a phase 3, multi-center study to assess a 10 percent intravenous immunoglobulin in adults with primary immunodeficiency disease
Jul 30, 2019: X4 Pharmaceuticals receives orphan drug designation from European Commission for Mavorixafor for treatment of WHIM syndrome
Jul 05, 2019: FDA approves Grifols’ Xembify for immunodeficiencies
Jun 26, 2019: X4 Pharmaceuticals initiates pivotal phase 3 clinical trial of Mavorixafor for the treatment of WHIM Syndrome
Apr 01, 2019: X4 Pharmaceuticals provides business and clinical development update
Dec 01, 2018: X4 Pharmaceuticals presents additional positive phase 2 results for X4P-001 in WHIM syndrome, continues on path to initiation of phase 3 trial
Nov 06, 2018: X4 Pharmaceuticals presents clinical data demonstrating single agent X4P-001-IO enhances tumor immunity through CXCR4 antagonism
Nov 01, 2018: X4 Pharmaceuticals to present clinical data used to determine phase 3 dose from phase 2/3 study of X4P-001-RD in WHIM syndrome
Oct 26, 2018: GigaGen to present data on Recombinant Hyperimmune Gammaglobulin at the 18th Biennial Meeting of the European Society for Immunodeficiencies
Oct 15, 2018: X4 Pharmaceuticals receives orphan drug designation from the U.S. FDA for X4P-001-RD for the treatment of WHIM syndrome
Sep 25, 2018: Evolve Biologics provides update on progress in phase III trial for PlasmaCap IG (Intravenous Immunoglobulin)
Jun 15, 2018: X4 Presents Data from Ongoing Phase 2 Study Demonstrating Promising Activity of X4P-001-RD in Patients with WHIM Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Primary Immune Deficiency (PID), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 6: Products under Development by Universities/Institutes, H2 2019
Table 7: Number of Products by Stage and Target, H2 2019
Table 8: Number of Products by Stage and Mechanism of Action, H2 2019
Table 9: Number of Products by Stage and Route of Administration, H2 2019
Table 10: Number of Products by Stage and Molecule Type, H2 2019
Table 11: Primary Immune Deficiency (PID) - Pipeline by ADMA Biologics Inc, H2 2019
Table 12: Primary Immune Deficiency (PID) - Pipeline by AlloVir Inc, H2 2019
Table 13: Primary Immune Deficiency (PID) - Pipeline by Biotest AG, H2 2019
Table 14: Primary Immune Deficiency (PID) - Pipeline by Cellective BioTherapy Inc, H2 2019
Table 15: Primary Immune Deficiency (PID) - Pipeline by Clinigen Group Plc, H2 2019
Table 16: Primary Immune Deficiency (PID) - Pipeline by Enzyvant Sciences Ltd, H2 2019
Table 17: Primary Immune Deficiency (PID) - Pipeline by Evolve Biologics Inc, H2 2019
Table 18: Primary Immune Deficiency (PID) - Pipeline by GC Pharma, H2 2019
Table 19: Primary Immune Deficiency (PID) - Pipeline by GigaGen Inc, H2 2019
Table 20: Primary Immune Deficiency (PID) - Pipeline by Grifols SA, H2 2019
Table 21: Primary Immune Deficiency (PID) - Pipeline by Liminal BioSciences Inc, H2 2019
Table 22: Primary Immune Deficiency (PID) - Pipeline by Mustang Bio Inc, H2 2019
Table 23: Primary Immune Deficiency (PID) - Pipeline by Octapharma AG, H2 2019
Table 24: Primary Immune Deficiency (PID) - Pipeline by Orchard Therapeutics Plc, H2 2019
Table 25: Primary Immune Deficiency (PID) - Pipeline by Rocket Pharmaceuticals Inc, H2 2019
Table 26: Primary Immune Deficiency (PID) - Pipeline by Sangamo Therapeutics Inc, H2 2019
Table 27: Primary Immune Deficiency (PID) - Pipeline by Taiga Biotechnologies Inc, H2 2019
Table 28: Primary Immune Deficiency (PID) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Table 29: Primary Immune Deficiency (PID) - Pipeline by X4 Pharmaceuticals Inc, H2 2019
Table 30: Primary Immune Deficiency (PID) - Dormant Projects, H2 2019
Table 31: Primary Immune Deficiency (PID) - Discontinued Products, H2 2019
List of Figures
Figure 1: Number of Products under Development for Primary Immune Deficiency (PID), H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Targets, H2 2019
Figure 5: Number of Products by Stage and Targets, H2 2019
Figure 6: Number of Products by Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
Figure 10: Number of Products by Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Molecule Types, H2 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook